Understand the source comparison
LL-37 Dosage Protocol Guide: Administration Method Comparison
Different research objectives require different delivery routes, each with distinct pharmacokinetic profiles and practical considerations. The table below compares the most common administration methods used in LL-37 research protocols. Subcutaneous Injection
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different research objectives require different delivery routes, each with distinct pharmacokinetic profiles and practical considerations. The table below compares the most common administration methods used in LL-37 research protocols.
- Subcutaneous Injection
- 2–10mg per site
- 70–85%
- 2–4 hours
- Requires precise injection technique; avoid repeat administration at the same site within 48 hours to prevent tissue irritation
- Sustained systemic exposure; immune modulation studies; multi-day protocols
- Topical Application
- 20–100 μg/mL solution
- 5–15% (local tissue)
- 30–90 minutes
- Limited systemic absorption; effective concentration confined to application site and immediate surrounding tissue
- Wound healing research; skin infection models; barrier function studies
- Intravenous Bolus
- 5–15mg per dose
- 100%
- Immediate (0–10 minutes)
- Requires sterile technique and appropriate catheter access; peptide must be dissolved in sterile saline only (no bacteriostatic water for IV use)
- Acute immune response studies; sepsis models; pharmacokinetic studies requiring precise Cmax measurement
- Intranasal Delivery
- 0.5–2mg per dose
- 30–50%
- 15–45 minutes
- Delivers peptide to nasal mucosa and respiratory epithelium with some systemic absorption; volume limited to 50–100 μL per nostril
- Respiratory infection models; mucosal immunity studies; CNS delivery via olfactory pathway
- Subcutaneous injection remains the most common route in published LL-37 research due to its balance of bioavailability, ease of administration, and reproducibility. Inject slowly over 5–10 seconds using a 25–27 gauge needle inserted at a 45-degree angle into the subcutaneous space. Typically the dorsal neck region or flank in rodent models. Rotate injection sites across multi-day protocols to prevent local inflammation that can alter peptide absorption.
- Topical application is straightforward but requires attention to formulation. LL-37 dissolved in sterile saline or phosphate-buffered saline (PBS) can be applied directly to wound beds or intact skin, but absorption is limited by the stratum corneum barrier. Some research protocols incorporate penetration enhancers or formulate LL-37 into hydrogel carriers to improve local retention and tissue penetration. A 2023 study in Biomaterials used LL-37-loaded hydrogels at 50 μg/mL to achieve sustained release over 72 hours in a porcine wound model.
- Intravenous administration achieves immediate systemic distribution but requires sterile preparation and appropriate catheter access. Never administer bacteriostatic water intravenously. The benzyl alcohol preservative is toxic when delivered systemically. Reconstitute LL-37 with sterile saline for IV use, and administer within 4 hours of preparation to minimise peptide degradation in solution.